Considerations for adding pneumonia and influenza vaccines to public health programmes

Vaccine

Volumn 17, Issue SUPPL. 1, 1999, Pages

  Miller, Mark A ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ANTIVIRAL ACTIVITY; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; HEALTH CARE POLICY; HIGH RISK POPULATION; IMMUNIZATION; INFLUENZA; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; PUBLIC HEALTH; SOCIOECONOMICS; VACCINATION; WORLD HEALTH ORGANIZATION;

EID: 0033618450     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00115-2     Document Type: Conference Paper

References (30)

1. World Health Organization, United Nations Children's Fund State of the world's vaccination and immunization. Geneva: WHO. 1996.
2. Fedson DS, Hirota Y, Shin HK, Cambillard PE, Kiely J, Ambrosch F, Hannoun C, Leese J, Sprenger MJ, Hampson AW, Bro-Jorgensen K, Ahlbom AM, Nokleby H, Valle M, Olafsson O, Salmeron F, Cloetta J, Rebelo de Andrade H, Snacken R, Donatelli I, Jennings LC, Strikas RA. Influenza vaccination in 22 developed countries: an update to 1995. Vaccine 1997;15:1506-11.
3. Centers for Disease Control and Prevention, Influenza and pneumococcal vaccination levels in persons > 65 years of age: 1973-1993, Morbid Mortal Wkly Rep 1995;506-515.
4. Aylward B, Kane M, Batson A, Scott RM. A framework for the evaluation of vaccines for use in the expanded programme on immunization. Vaccine 1994;12:1155-9.
5. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994;22;331:778-84.
6. Nichol KL, Lind A, Margolis KL, Murdoch M, McFadden R, Hauge M, Magnan S, Drake M. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 1995;333:889-93.
7. Schonberger LB, Hurwitz ES, Katona P, Holman RC, Bregman DJ. Guillain-Barre syndrome: its epidemiology and associations with influenza vaccination. Ann Neurol 1981;9(Suppl.):31-8.
8. Bolan G, Broome CV, Facklam RR, Plikaytis BD, Fraser DW, Schlech III WF. Pneumococcal vaccine efficacy in selected populations in the United States. Ann Intern Med 1986;104:1-6.
9. Klarman H, Guzick D. Economics of influenza. In: Selby P, editor. Influenza: virus, vaccine and strategy. New York: Academic Press, 1976.
10. Schoenbaum S, McNeil N, Kavet J. The swine-influenza decision. N Engl J Med 1976;295:759-65.
11. Kavet J. A perspective on the significance of pandemic influenza. Am J Public Health 1977;67:1063-70.
12. Elo O. Cost-benefit studies of vaccinations in Finland. Dev Biol Stand 1979;43:419-28.
13. Office of Technology Assessment. A review of selected Federal vaccine and immunization policies based on case studies of pneumococcal vaccine. Washington DC: US Government Printing Office, 1979 052-003-00701-1, September.
14. Willems JS, Sanders CR, Riddiough MA, Bell JC. Cost-effectiveness of vaccination against pneumococcal pneumonia. N Engl J Med 1980;303:553-9.
15. Office of Technology Assessment. Cost effectiveness of influenza vaccination. Washington DC: US Government Printing Office, 1981 December.
16. Riddiough MA, Sisk JE, Bell JC. Influenza vaccination. JAMA 1983;249:3189-95.
17. Patriarca PA, Arden NH, Koplan JP, Goodman RA. Prevention and control of type A influenza infections in nursing homes. Benefits and costs of four approaches using vaccination and amantadine. Ann Intern Med 1987;107:732-40.
18. Schoenbaum SC. Economic impact of influenza. The individual's perspective. Am J Med 1987;82:26-30.
19. Maucher JM, Gambert SR. Cost-effective analysis of influenza vaccination in the elderly. Age 1990;13:81-5.
20. Yassi A, Kettner J, Hammond G, Cheang M, McGill M. Effectiveness and cost-benefit of an influenza vaccination program for health care workers. Can J Infect Dis 1991;2:101-8.
21. Rose DN, Schechter CB, Sacks HS. Influenza and pneumococcal vaccination of HIV-infected patients: A policy analysis. American J Med 1993;94:160-8.
22. Mullooly JP, Bennett MD, Hornbrook MC, Barker WH, Williams WW, Patriarca PA, Rhodes PH. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med 1994;121:947-52.
23. Campbell DS, Rumley MH. Cost-effectiveness of the influenza vaccine in a healthy, working-age population. J Occup Environ Med 1997;39:408-14.
24. Patrick KM, Wooley FR. A cost-benefit analysis of immunization for pneumococcal pneumonia. JAMA 1981;245:473-7.
25. Office of Technology Assessment. Update of Federal activities regarding the use of pneumococcal vaccine. Washington DC: US Government Printing Office, 1984 OTA-TM-H-23, May.
26. Sisk JE, Riegelman RK. Cost effectiveness of vaccination against pneumococcal pneumonia: an update. Ann Intern Med 1986;104:79-86.
27. Sisk JE, Moskowitz AJ, Whang W, Lin JD, Fedson DS, McBean AM, Plouffe JF, Cetron MS, Butler JC. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997;278:1333-9.
28. Noble GR. Epidemiological and clinical aspects of influenza. In: Beare AS, editor. Basic and applied influenza research. Boca Raton, Florida: CRC Press, 1982. p. 11-50.
29. Simonsen L, Clarke MJ, Schonberger LB, Arden NH, Cox NJ, Fukada A, A pandemic versus epidemic influenza mortality: a pattern of changing age distribution, J Infect Dis 1998;178:53-60.
30. Batson A. Win-win interactions between the public and private sectors. Nature Med 1998;4:487-91.